Immatics Company Insiders
| IMTX Stock | USD 7.18 0.09 1.24% |
Immatics employs about 542 people. The company is managed by 21 executives with a total tenure of roughly 1265 years, averaging almost 60.0 years of service per executive, having 25.81 employees per reported executive. Break down of Immatics' management performance can provide insight into the company performance.
Immatics |
Immatics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1217) % which means that it has lost $0.1217 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2432) %, meaning that it created substantial loss on money invested by shareholders. Immatics' management efficiency ratios could be used to measure how well Immatics manages its routine affairs as well as how well it operates its assets and liabilities.Immatics Workforce Comparison
Immatics NV is currently regarded as number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,819. Immatics retains roughly 542 in number of employees claiming about 19% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.04) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.42) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.42. Immatics NV Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Immatics NV Price Series Summation is a cross summation of Immatics price series and its benchmark/peer.
Immatics Notable Stakeholders
An Immatics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Immatics often face trade-offs trying to please all of them. Immatics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Immatics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Kristijan Lasic | Director Accounting | Profile | |
| Andrea Mokler | VP Sciences | Profile | |
| Miriam Meyer | VP Affairs | Profile | |
| Evelyn RothGeissler | VP Operations | Profile | |
| Emmanuelle MBA | VP Head | Profile | |
| PHR MBA | Director HR | Profile | |
| Edward Sturchio | General Secretary | Profile | |
| Arnd MBA | Chief Officer | Profile | |
| Toni Weinschenk | CoFounder Officer | Profile | |
| Anja BSc | Director Communications | Profile | |
| Carsten MD | Chief Officer | Profile | |
| HansGeorg Rammensee | CoFounder Board | Profile | |
| Steffen Walter | Chief Officer | Profile | |
| Cedrik MD | Chief Officer | Profile | |
| Dominik Maurer | Senior Unit | Profile | |
| Edward JD | General Secretary | Profile | |
| Harpreet Singh | MD, CEO | Profile | |
| Ali Mohamed | Senior CMC | Profile | |
| Ephraim MSc | Vice Accounting | Profile | |
| Rainer Kramer | Chief Munich | Profile | |
| Jordan Silverstein | Head Strategy | Profile |
About Immatics Management Performance
The success or failure of an entity such as Immatics NV often depends on how effective the management is. Immatics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Immatics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Immatics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers and Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 388 people.
Please note, the imprecision that can be found in Immatics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immatics NV. Check Immatics' Beneish M Score to see the likelihood of Immatics' management manipulating its earnings.
Immatics Workforce Analysis
Traditionally, organizations such as Immatics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Immatics within its industry.Immatics Manpower Efficiency
Return on Immatics Manpower
| Revenue Per Employee | 99.6K | |
| Revenue Per Executive | 2.6M | |
| Net Loss Per Employee | 179K | |
| Net Loss Per Executive | 4.6M | |
| Working Capital Per Employee | 540.3K | |
| Working Capital Per Executive | 13.9M |
Additional Tools for Immatics Stock Analysis
When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.